Mushrooms, a public biotech company pioneering advancements in mycelium-based innovation, is pleased to announce the acquisition of MYCOLabX INC as a wholly owned subsidiary.
This strategic acquisition consolidates early-stage technology development, legacy investment structures, and proprietary R&D assets into a dedicated biotech platform under the Mushrooms Inc. umbrella. The transaction enhances operational clarity, reduces public company liabilities, and provides increased investment flexibility.
“As our technologies progress, this acquisition helps clarify our structure and strengthen our operations without diluting shareholder value,” said Kimberly Carlson, CEO of Mushrooms Inc.
